BGM Group Ltd.
Description
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
About
CEO
Mr. Zhanchang Xin
Employees
298
Instrument type
Common Stock
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
MIC code
XNCM
Address
No. 152 Hongliang East 1st Street, Chengdu, 610200, China
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Feb 11, 2022 | — | 0.09 | — | — |
| Sep 16, 2021 | — | 0.07 | — | — |
| Feb 11, 2021 | — | 0.17 | — | — |
Earnings estimate
| Number of analysts | — | — | — | — |
|---|---|---|---|---|
| Average estimate | — | — | — | — |
| Low estimate | — | — | — | — |
| High estimate | — | — | — | — |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr.
—
Current year
—
Next year
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total reported revenue | 25.10M | 46.47M | 64.86M | 57.10M | 50.03M |
| Cost of revenue | 20.98M | 44.72M | 58.63M | 51.46M | 42.49M |
| Gross profit | 4.11M | 1.75M | 6.23M | 5.64M | 7.54M |
| Operating expense | |||||
| Research & development | 1.36M | 568,470 | 1.22M | — | — |
| Selling general and admin | 3.32M | 3.79M | 2.90M | 3.25M | 2.73M |
| Other operating expenses | -206,415 | -192,375 | -413,717 | -564,098 | -1.08M |
| Operating income | -357,356 | -2.42M | 2.52M | 2.95M | 5.89M |
| Non operating interest income | |||||
| Income | — | — | 24,860 | — | — |
| Expense | — | — | — | 57,671 | 242,877 |
| Other income expense | -1.14M | -5.58M | -980,021 | 468,805 | 155,029 |
| Pretax income | -2.14M | -7.90M | 1.56M | 3.36M | 5.81M |
| Tax provision | -619,981 | 219,166 | 194,302 | 255,133 | 864,908 |
| Net income | -1.52M | -8.12M | 1.37M | 3.11M | 4.94M |
| Basic EPS | — | -1.08 | 0.15 | 0.09 | 0.14 |
| Diluted EPS | — | -1.08 | 0.15 | 0.09 | 0.14 |
| Basic average shares | — | 7.23M | 7.23M | 34.09M | 35.00M |
| Diluted average shares | — | 7.23M | 7.23M | 34.09M | 35.00M |
| EBITDA | 1.80M | 4.25M | 4.55M | 3.69M | 7.16M |
| Net income from continuing op. | -1.52M | -8.12M | 1.37M | 3.11M | 4.94M |
| Minority interests | 74,331 | 341,450 | -289,564 | 44,724 | 123,269 |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 |
| Total assets | 53.00M | 51.26M | 64.53M | 75.35M | 48.14M |
| Current assets | |||||
| Cash | — | — | — | — | 11.87M |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 9.82M | 7.48M | 14.32M | 10.47M | 11.87M |
| Other short term investments | 8.32M | 14.94M | — | — | — |
| Accounts receivable | 1.54M | 1.98M | 815,325 | 1.73M | 1.12M |
| Other receivables | 192,387 | 247,481 | 1.47M | 14,090 | 8,126 |
| Inventory | 5.05M | 4.99M | 8.88M | 12.50M | 11.99M |
| Prepaid assets | 803,924 | 747,331 | 1.30M | 1.79M | 646,297 |
| Restricted cash | — | — | 659,779 | 2.14M | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | -1 | — | — |
| Non current assets | |||||
| Properties | — | — | — | — | 243,874 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 19.20M | 18.31M | 19.05M | 20.43M | 18.93M |
| Construction in progress | 6.30M | 3.50M | 3.22M | 4.26M | 158,975 |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -24.11M | -22.06M | -21.92M | -23.05M | -20.78M |
| Goodwill | 4.54M | 3.42M | 1.73M | 1.93M | 1.88M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 4.54M | 3.42M | 1.73M | 1.93M | 1.88M |
| Investments and advances | 3.36M | 606,005 | 20.09M | 20.96M | 540,517 |
| Other non current assets | 424,474 | 10,778 | 385,787 | 616,033 | 540,575 |
| Total liabilities | 8.91M | 6.91M | 9.56M | 18.68M | 19.30M |
| Current liabilities | |||||
| Accounts payable | 4.13M | 3.59M | 5.29M | 6.64M | 4.38M |
| Accrued expenses | 915,032 | 1.21M | 701,263 | 466,838 | 1.30M |
| Short term debt | — | 553,275 | 1.70M | 7.92M | 7.43M |
| Deferred revenue | 568,502 | 1.11M | 677,960 | 2.84M | 3.93M |
| Tax payable | 315,328 | 203,498 | 815,811 | 305,305 | 1.38M |
| Pensions | — | — | — | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | — | 24,575 | 72,537 | 106,180 | 155,723 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | — | — | — | — | — |
| Shareholders equity | |||||
| Common stock | 59,583 | 59,583 | 59,583 | 59,583 | 50,000 |
| Retained earnings | 4.35M | 5.90M | 15.51M | 14.69M | 12.20M |
| Other shareholders equity | 1.92M | 425,246 | 1.07M | 3.71M | 1.60M |
| Total shareholders equity | 44.09M | 44.35M | 54.96M | 56.67M | 28.84M |
| Additional paid in capital | 36.41M | 36.41M | 36.41M | 36.39M | 12.25M |
| Treasury stock | — | — | — | — | — |
| Minority interest | 1.35M | 1.56M | 1.91M | 1.81M | 2.74M |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | -1.52M | -8.12M | 1.37M | 3.11M | 4.94M | 5.91M | 5.20M | 1.54M |
| Depreciation | 1.24M | 1.14M | 1.22M | 1.20M | 1.17M | 1.19M | 1.25M | 1.24M |
| Deferred Taxes | -406,845 | 203,544 | 189,838 | -46,187 | -86,495 | 48,656 | 15,799 | 57,510 |
| Stock-Based Compensation | — | — | 20,000 | — | — | — | — | — |
| Other Non-Cash Items | 60,785 | 25,982 | 22,450 | 62,410 | — | — | — | — |
| Accounts Receivable | 1.33M | -2.89M | 9.77M | -157,502 | -6.24M | -1.46M | -4.06M | 1.86M |
| Accounts Payable | 378,976 | -1.62M | -805,443 | 2.02M | 613,339 | -50,041 | -824,545 | 2.72M |
| Other Assets & Liabilities | -1.32M | 5.20M | -1.14M | -2.63M | 2.64M | -6.07M | 2.12M | -4.70M |
| Operating Cash Flow | -235,825 | -6.06M | 10.65M | 3.55M | 3.03M | -442,232 | 3.70M | 2.73M |
| Investing Activities | ||||||||
| Capital Expenditures | -2.85M | -1.85M | -3.23M | -3.49M | -449,766 | -616,388 | -1.12M | -1.52M |
| Net Intangibles | -1.08M | -1.87M | -26,683 | -1,810 | -8,798 | -635 | — | -7,125 |
| Net Acquisitions | — | -28,356 | — | -706,658 | — | -133,552 | — | — |
| Purchase of Investments | -1.40M | -1.00M | — | -20.00M | — | -64,165 | -268,905 | -159,236 |
| Sale of Investments | 6.26M | — | — | — | 82,972 | 14,559 | — | — |
| Investing Cash Flow | 2.01M | -2.88M | -3.23M | -24.20M | -366,794 | -799,546 | -1.39M | -1.68M |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | — | — | 3.20M | 7.80M | 7.14M | 5.09M | — | 1.75M |
| Long-Term Debt Payments | -491,728 | -1.69M | -9.14M | -7.68M | -4.99M | -4.22M | -2.63M | — |
| Other Financing Charges | — | 56,711 | — | — | — | -365,310 | 247,700 | -493,139 |
| Financing Cash Flow | -983,456 | -4.61M | -11.88M | 16.31M | -2.85M | -74,472 | -4.22M | 2.90M |
| Other Cash Details | ||||||||
| End Cash Position | 9.82M | 7.48M | 14.98M | 12.61M | 11.87M | 4.59M | 5.62M | 5.37M |
| Income Tax Paid | 21,910 | 27,440 | — | 820,972 | 275,607 | 1.11M | 658,409 | 48,003 |
| Interest Paid | 4,262 | 3,656 | 122,237 | 152,499 | 280,169 | 210,588 | 223,773 | 281,701 |
| Free Cash Flow | -3.39M | -3.40M | 9.40M | -3.15M | 4.62M | -1.20M | 3.32M | 1.15M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 4,729 | 49,938 | 0.01% |
Article
BMG Completed Acquisition of High-Quality Assets, Marking a New Chapter in Diversified Growth
CHENGDU, China , Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Nasdaq: BGM) (the "Company" or "BGM"), a leading global pharmaceutical enterprise, today announced completion of the acquisition of the intelligent platform of AIX Inc. It marks BGM's official entry into the domains of AI intelligent technology and financial/insurance services, opening up new opportunities for the integrated development of healthcare, pharmaceuticals, and insurance on a global scale.
Dec 27, 2024
Article
In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI
CHONGQING, China , Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired Rongshu Technology and Xinbao Investment Company, both subsidiaries of AIX Corp. (Stock Code: AIFU), in a transaction valued at approximately $140 million.
Dec 27, 2024
Article
BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development
CHENGDU, China , Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr.
Dec 19, 2024
